Clinical trial
An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain
NCT00911261 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2003
- Completion date
- May 31, 2005
- Enrollment
- 223 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, chronic pain, neuropathic pain